U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.
Key Financial Performance
Gross Profit Grew 30% year-over-year. Even after adjusting for anomalies from the previous year, there was still a mid-teens percentage increase. This growth occurred despite inflationary pressures and higher staff costs.
Average Visits Per Clinic Per Day Reached a record of 32.2 for Q3, marking the highest third-quarter volume in the company's history. This was driven by strong patient care and service.
Total Patient Visits Increased 18% year-over-year, supported by the addition of 84 net owned clinics and a 2.2% increase in visits at mature clinics.
PT Salaries and Related Costs Per Visit Decreased by $0.40 per visit compared to the prior year, marking the first decline since Q4 2023. This was achieved through cost management initiatives.
IIP Revenue Grew almost 15% year-over-year, with gross profit up nearly 11%. This growth was entirely organic.
Adjusted EBITDA Increased by $2.8 million or 13.2% year-over-year, reaching $23.9 million. This reflects strong operational performance.
Net Rate Per Patient Visit Was $105.54 for Q3, slightly down from the same quarter last year but up modestly from Q2 2025. September saw the highest monthly net rate of the year, exceeding $106 per visit.
Physical Therapy Revenues Increased by $25.4 million or 17.8% year-over-year, reaching $168.1 million. Most of this growth came from acquisitions, with Metro and PT in New York contributing $19.5 million.
Physical Therapy Operating Costs Increased by $18.2 million or 15.3% year-over-year, totaling $136.9 million. However, total operating cost per visit increased by just 1%, reflecting effective cost management.
Physical Therapy Operating Margin Was 18.6%, reflecting strong operational efficiency.
IIP Net Revenues Increased by $3.7 million or 14.6% year-over-year, with income rising by $546,000 or 10.7%. This growth was entirely organic.
Corporate Expenses Were 8.5% of net revenue, slightly down from 8.6% in Q3 2024, reflecting effective cost control.
Operating Results Were $10.1 million, down slightly from $10.4 million a year ago. The decline was due to lower interest income and higher interest expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Remote Therapeutic Monitoring: The company plans to reinitiate remote therapeutic monitoring in 2026, leveraging a fully integrated app with their EMR system. CMS has reduced the number of visits required for a billable code, which is expected to improve patient outcomes and engagement.
Clinic Expansion: The company added 84 net new PT facilities over the last year, contributing to an 18% increase in total patient visits year-over-year.
Workers' Compensation Business: The company is focusing on expanding its higher-rate workers' compensation business and expects to add several new network relationships before the end of the year.
Operational Efficiencies: The company is implementing AI-driven documentation and semi-virtualization of front desk operations, targeting 200 facilities by year-end. These initiatives aim to improve efficiency and reduce costs.
Cost Management: PT salaries and related costs per visit decreased by $0.40 year-over-year, marking the first decline since Q4 2023. Total operating costs per visit increased by only 1% despite inflationary pressures.
Medicare Reimbursement: CMS's final rule for 2026 includes a slight increase in manual therapy reimbursement and reduced visit requirements for remote therapeutic monitoring, providing a positive outlook for Medicare reimbursement.
Injury Prevention Business: The company continues to grow its injury prevention business, achieving 14.6% revenue growth and 10.7% income growth year-over-year, all organically. It plans to expand industry verticals and service opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Reimbursement Cuts: The company has faced significant Medicare reimbursement cuts over the years, aggregating to over 11%, with a $25 million profit impact in 2025 alone. This remains a persistent headwind for the business.
Inflationary Pressures: The company operates in an inflationary environment where staff costs and other operational expenses are rising, although some cost management initiatives have been implemented.
Regulatory and Compliance Challenges: The company faces challenges related to regulatory changes, such as the CMS final rule and geographic index factors, which require constant adaptation and analysis.
Integration of New Technologies: The rollout of AI-driven documentation and semi-virtualization of front desk operations is still in its early stages, requiring time and resources to fully implement and realize benefits.
Remote Therapeutic Monitoring: The company has struggled with the rollout of remote therapeutic monitoring due to integration challenges and clunky processes, although improvements are expected in 2026.
Acquisition and Expansion Risks: The company has added 84 net PT facilities, but this rapid expansion comes with risks related to integration, operational efficiency, and maintaining service quality.
Interest Rate and Debt Management: Higher interest expenses due to increased debt levels and reliance on a revolving credit facility could impact financial flexibility.
Seasonal and Market Variability: Patient visit volumes show seasonal patterns, and shifts in payer mix (e.g., Medicare vs. workers' compensation) could affect revenue and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Medicare Reimbursement: The company anticipates some positive changes in Medicare reimbursement starting in 2026, including a reversal of manual therapy reductions and improved rules for remote therapeutic monitoring. This is expected to provide a more favorable reimbursement environment.
Remote Therapeutic Monitoring: The company plans to reinitiate remote therapeutic monitoring in 2026, leveraging a fully integrated app and improved CMS rules. This initiative is expected to enhance patient outcomes and engagement.
Efficiency Initiatives: The company is rolling out AI-driven documentation and semi-virtualization of front desk operations, targeting 200 facilities by year-end 2025. These initiatives aim to improve operational efficiency and patient flow.
Injury Prevention Business: The company plans to continue expanding its injury prevention business, with additional opportunities in the pipeline and a focus on growing industry verticals and service lines.
Capital Allocation: Acquisitions remain the primary capital allocation priority, with a focus on long-term growth strategy. The company has not repurchased shares under its share repurchase program.
Adjusted EBITDA Guidance: The company reaffirmed its adjusted EBITDA guidance for full year 2025 to be in the range of $93 million to $97 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We've not yet repurchased any shares under the share repurchase program we established in August. We view that as a prudent tool to have at our disposal, but acquisitions will continue to be our primary capital allocation priority, consistent with our long-term growth strategy.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are you seeing in the demand environment for physiotherapy and clinician recruitment and retention?
A:Demand has been strong throughout the year, with some fluctuations between months. July was unexpectedly strong, August was softer, and September rebounded. Investments in recruiting, tracking platforms, and school relationships have improved recruitment and retention. Turnover is low, and salaries remain competitive.
Q:How are you thinking about opportunities on the M&A side versus share buybacks?
A:Acquisitions are prioritized over share buybacks as they provide better returns. The focus is on IIP acquisitions due to better revenue and profit growth prospects. PT acquisitions will continue, but IIP is the main focus to grow that segment.
Q:Can you discuss competitive dynamics in physical therapy across your markets?
A:Competition comes from small practices, hospital-based practices, and large providers. Larger PE-backed companies have been balance sheet-constrained, leading to lower acquisition multiples. The company benefits from a strong balance sheet, allowing for long-term investments and resource deployment.
Q:Can you parse out core growth figures across Medicare, commercial, and workers' comp?
A:In mature clinics, commercial visits grew 2.5%-3%, Medicare visits grew 4.5%, and workers' comp visits dipped slightly. Overall visit growth was 2.2%, and revenue growth was slightly positive due to a mix shift favoring lower-rate payers like Medicare.
Q:What is the updated estimate of the Medicare rate impact on adjusted EBITDA?
A:The final Medicare rate impact is not yet determined, but the expected increase is now seen as a floor of 1.5%, with potential for a slightly higher figure. More details will be provided in the next call.
Q:What are the tailwinds and headwinds for next year?
A:Tailwinds include cost-saving initiatives like AI-driven documentation and remote therapeutic monitoring. There are no significant headwinds expected, as the Medicare rate headwind has been resolved.
Q:What is causing the reversals of payouts from acquisitions?
A:Reversals are due to quarterly re-projections of earn-out periods based on actual performance. Lofty targets are set for acquisitions, and adjustments are made if targets are not met.
Q:Why were mature clinic volumes flat, and how can they improve?
A:Efforts to reduce costs may have slightly impacted volumes. Efficient resource allocation is prioritized, but this can limit the ability to handle walk-ins. Slack resources could help improve volumes.
Q:Will the new ERP system provide efficiency benefits?
A:Yes, the ERP system will improve efficiency in finance, accounting, and HR. It will provide quicker and more comprehensive information for business management.
Q:Is mid-teens growth in the injury prevention (IIP) segment sustainable?
A:Mid-teens growth is considered sustainable, supported by cross-selling opportunities and the addition of new programs. The IIP segment is expected to grow faster than the PT business.
Q:What is the status of home-care visits and their margins?
A:Home-care visits are primarily in the Northeast, with expansion opportunities. Margins are favorable in the Northeast due to high Medicare reimbursement rates and manageable labor costs. Margins may vary in other regions.
Q:What is the limiting factor for de novo clinic growth?
A:The main limiting factor is finding the right leadership for new facilities and backfilling their previous roles. Partners must also be willing to invest in new facilities. The company plans to discuss strategies to accelerate de novo growth in the future.
Q:Why did the gross margin in the IIP segment decline sequentially?
A:The decline was due to a reallocation of amortization expenses from the PT segment to the IIP segment. This adjustment will be applied prospectively.
Q:What percentage of overall revenue was workers' comp this quarter?
A:Workers' comp accounted for 9.7% of overall revenue. Visits grew 5% year-over-year, and revenue increased nearly 10% due to higher rates and new contracts.
Q:What is the expected range for the Medicare update for 2026?
A:The Medicare update is expected to be around 1.5%-1.7%, with a potential ceiling of 2% if remote therapeutic monitoring is effectively implemented.
Q:Are affordability concerns affecting therapy durations?
A:No, therapy durations have remained consistent, even during periods of high inflation. October volumes have been strong, indicating no impact from affordability concerns.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the final Medicare rate impact on adjusted EBITDA, stating that the calculation is complex and not yet finalized. They also refrained from discussing specific details about upcoming initiatives and strategies for accelerating de novo growth, indicating that more information will be shared in future updates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI documentation
APTQI others
Accounting Treasury
CMS couple
CMS encouragement
CMS patient
Deals information
EMR reinitiation
EMR system
East Executive
Executive VP
Friday table
Full Conference
IIP margin
Instructions
Limber
basis point
bunch
care visit
category
change
code
decline
function
industry vertical
interest income
monitoring
patient door
promoter score
rate worker
revolver
rule
salary visit
service line
share
tool
volume clinic
USPH Transcript
U.S. Physical Therapy, Inc. (USPH) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary shows mixed signals: financial performance was affected by weather and increased expenses, leading to a decrease in net income and cash reserves. However, the company maintains confidence in achieving its annual guidance and sees potential in hospital partnerships. The Q&A reveals concerns about unpredictable hospital deals and management's avoidance of detailed guidance. The market cap suggests moderate sensitivity to these factors. Overall, the sentiment is balanced, with positive long-term strategies offset by short-term financial challenges.
U.S. Physical Therapy, Inc. (USPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call showed strong financial performance with increased revenues, margins, and EBITDA. The Q&A highlighted positive growth prospects, efficient cost management, and strategic acquisitions. Despite some concerns about wage inflation and unclear details on hospital rates, the company's optimistic guidance, improved margins, and strategic initiatives like AI-driven operations and acquisitions suggest a positive outlook. Given the company's market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.
U.S. Physical Therapy, Inc. (USPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance, with significant revenue and margin growth, and positive developments in acquisitions and injury prevention. The Q&A indicates solid demand and effective labor management strategies, with AI tools enhancing efficiency. The introduction of a buyback program and slight commercial rate increases further boost sentiment. While there are some uncertainties, such as Medicare rate changes and staffing challenges, the overall outlook is optimistic. Given the company's small-cap status, the positive factors are likely to result in a stock price increase of 2% to 8%.
USPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
